BeOne Medicines AG
ONC
Get informed when a big investor buys or sells
+ FollowMarket Cap$42.13B
Close$
Share Statistics
| Market cap | $42.13 Billion |
|---|---|
| Enterprise Value | $38.26 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $33.8 |
| Beta | 0.52 |
| Outstanding Shares | 111,575,811 |
Return
| Return on Equity | 12.67% |
|---|---|
| Return on Assets | 7.15% |
| Return on Invested Capital | 13.78% |
Valuation & Multiples
| P/E Ratio | 27.82 |
|---|---|
| PEG | 18.39 |
| Price to Sales | 6.99 |
| Price to Book Ratio | 8.21 |
| Enterprise Value to Revenue | 6.24 |
| Enterprise Value to EBIT | 39.33 |
| Enterprise Value to Net Income | 58 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.24 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$1.63
Average shareholder expectationRevenue Estimate
$1.62 B
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$1.89
Average shareholder expectationRevenue Estimate
$1.75 B
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 72.81% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.15%▼ 31.19% |
|---|---|
| Total Invested | $58.62M▼ 99.41% |
| Investors Holding | 40▼ 256.00% |
ESG Score
No data
About BeiGene Ltd
12,000 employees
CEO: John Oyler BeOne Medicines AG, an oncology-focused enterprise headquartered in Basel, Switzerland, was established in 2010. This company is actively involved in the exploration and advancement of a diverse range of therapeutic solutions for cancer ...